IMMUNOVATIVE ANNOUNCES QC RELEASE OF FIRST 1271 COMPLIANT BATCH

Immunovative today announces that it has released its first batch of AlloStim produced with blood collected in compliance with 21 CFR 1271 regulations.  These cells will be used in our Phase II clinical trial in metastatic colorectal cancer being conducted at Banner-MD Anderson Medical Center in Phoenix, AZ.

SPECIALITY INFORMATION

patients


Treatment strategy designed to use the power of the human immune system to kill tumors and prevent their recurrence.
No requirement for a matched donor or chemotherapy/radiation conditioning prior to treatment.
Innovative technology – proven and non-toxic.
read more

Healthcare professionals


Therapeutic anti-tumor vaccine developed from core break-through technology called the "Mirror Effect™“ which opens a pathway to treating patients with metastatic cancer that have failed all available therapy options.
Elicits a GVT-like mechanism without the GVHD toxicity.
read more

Investors


Privately-held Israeli biopharmaceutical company spin out from Hadassah-Hebrew University Medical Center with headquarters in Jerusalem.

Over 200 individual private shareholders and grant support from the Israel Office of the Chief Scientist.
read more